By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Panelists agree that Insperity's margin recovery is fragile, with core PEO volumes shrinking and significant uncertainty around the UnitedHealthcare contract shift and macroeconomic conditions. Growth recovery is speculative, and the valuation remains sensitive to macro headwinds.
Risk: The shift in the UnitedHealthcare contract effectively back-loads earnings risk to the second half of the year, creating significant uncertainty and a fundamental increase in underwriting risk.
Opportunity: HRScale's 6k committed WSEs is promising but unproven at scale vs 300k base.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Insperity reported a Q1 beat with adjusted EPS $1.31 and adjusted EBITDA $103 million, driven by improving gross-profit trends and tighter operating expense management as part of a multi-year margin recovery plan.
Average paid worksite employees fell to 303,049 (down ~1%) as new-client sales were weaker and attrition was 11%, prompting a lowered WSE outlook of 303,000–307,000 for 2026 while the company maintained full-year adjusted EBITDA guidance of $170M–$230M and an EPS range of $1.60–$2.60.
The new UnitedHealthcare agreement (pooling limit cut to $500k) will back-load claim reimbursements and alter quarterly seasonality, while Insperity’s HRScale rollout — with beta clients onboarded and ~6,000 WSEs committed — is positioned as a key growth and competitive-differentiation catalyst.
Insperity (NYSE:NSP) reported first-quarter 2026 results that exceeded the midpoint of management’s expectations, led by improved gross profit trends and operating expense management as the company works through a multi-year margin recovery plan. Adjusted earnings per share were $1.31 and adjusted EBITDA was $103 million, both above the midpoint of the company’s expected range, according to Executive Vice President of Finance, CFO and Treasurer James Allison.
First-quarter results: margin recovery progress offsets softer unit growth
Insperity’s average paid worksite employees (WSEs) were 303,049 in the quarter, down 1.0% versus the first quarter of 2025 and at the low end of the company’s forecast range. Allison said quarterly performance reflected “outperformance in gross profit and operating expense management, partially offset by slightly lower than expected unit growth.”
New client sales contributed to the WSE softness. Allison said worksite employees paid from new client sales declined 7% compared with the prior-year quarter. Client attrition totaled 11% in Q1 2026, within the company’s historical 9% to 12% range. He added that net hiring within the client base was in line with forecasts and slightly higher than Q1 2025, but “occurred later in the quarter than we had expected,” which lowered the average WSE count for the period.
Total gross profit decreased 3% year over year to $302 million, which Allison characterized as a sharp improvement from the 21% gross profit decline experienced in Q4 2025. Gross profit per worksite employee was $332 per month, “slightly above our forecast and within our range of expectations,” driven mainly by lower-than-expected benefit costs.
Benefits cost per covered employee increased 5% over Q1 2025, an improvement from the roughly 9% trend seen during 2025. Allison attributed the improvement largely to favorable client mix changes tied to pricing and retention strategy, benefit plan design changes, and new contract terms with UnitedHealthcare.
Management emphasized that the new UnitedHealthcare agreement is expected to alter the company’s typical quarterly earnings seasonality. Allison said Insperity anticipates “less expected earnings early in the year and more expected earnings later in the year,” largely due to a pooling limit change from $1 million per member per year to $500,000.
Under the new structure, Allison explained, Insperity is paying a higher fixed premium charged evenly throughout the year, while claim reimbursements are expected to be “significantly weighted towards the latter quarters of the year.” He reiterated later that the contract’s financial impact should be “more back-end loaded” than some may have assumed.
Allison also cited several factors that helped Q1 benefit costs come in better than expected, including “slightly favorable runoff of prior period claims, reduced large claim activity, and lower than expected pharmacy claims,” while noting the company remained cautious about the range of outcomes for the rest of the year.
Expenses, restructuring, and HRScale spending
Total operating expenses declined 1% to $240 million, including a $9 million restructuring charge primarily related to severance tied to a workforce realignment. Excluding the charge, operating expenses fell 5% year over year.
Insperity invested $13 million in HRScale during the quarter, comprising $8 million in operating expenses and $5 million of capitalized costs. Allison noted that in Q1 2025, the company also spent $13 million on HRScale, but that amount was fully expensed in that period.
Adjusted EPS declined 17% year over year to $1.31, reflecting a higher effective income tax rate of 41% versus 29% in Q1 2025. Allison said the change was primarily due to Insperity’s lower stock price reducing tax benefits associated with stock compensation vesting, which largely occurs in the first quarter. He said the effective tax rate is expected to normalize for the remainder of the year.
Capital return and liquidity
During the quarter, Insperity paid $23 million in dividends and repurchased 171,000 shares for $4 million. The company ended Q1 with $36 million of adjusted cash, which Allison said reflected seasonal working capital timing related to corporate payroll, healthcare, and software maintenance contract funding.
As of March 31, 2026, Insperity had $380 million in unused capacity under its credit facility, with about $330 million available to borrow, Allison said.
Growth outlook: HRScale rollout and macro uncertainty
Chairman and CEO Paul Sarvadi said the company’s three-year plan prioritizes margin recovery in year one, with regaining growth momentum as the second priority in 2026. He said margin recovery drivers include the UnitedHealthcare agreement, plan design changes, strategic pricing and client selection, and operating efficiency improvements, with the goal of “a substantially full recovery as we move into 2027.”
On growth, Sarvadi said booked sales in Q1 were below internal targets “except for our Insperity HR360 mid-market sales,” and that process changes tied to margin recovery pressured both sales and retention. He said the company has implemented key learnings intended to improve booked sales performance over the balance of the year.
Sarvadi highlighted progress on HRScale, noting that initial beta clients were onboarded in March and that “payrolls and invoices were processed in April as scheduled.” He said the HRScale pipeline is building and described the offering as combining Insperity’s HR services and compliance expertise with Workday client-facing technology. Sarvadi said the company has “signed commitments for nearly 6,000 worksite employees to be on board within the next 6 months.”
He also said HRScale is intended to address what he called Insperity’s “historical success penalty,” where growing clients leave for technology built for larger firms, and to expand new client opportunities in businesses with 150 to 5,000 employees. Sarvadi added that prospects view HRScale as a “lower-risk decision” due to lower upfront investment, faster time to value, and lower ongoing costs compared with typical mid-market HCM and HR service combinations.
On retention, Sarvadi said attrition has been at the higher end of historical levels, but the company is seeing “the desired impact” because a greater share of departing clients were less profitable. He said attrition is expected to remain slightly higher but moderate as the year progresses.
Macro conditions were a central theme. Sarvadi cited Insperity’s Business Outlook Survey showing small and mid-sized businesses becoming more cautious since January. He said 54% of respondents expect a negative business impact, up from 42% in January, while 25% foresee positive effects, down from 37%. While 64% still expect to perform better in 2026 than 2025, that figure declined from 70% in January, he said.
In response, management lowered its worksite employee outlook but reiterated adjusted EBITDA guidance. Allison said the company is forecasting full-year 2026 average paid WSEs of 303,000 to 307,000, a decline of 1% to 2.3% from 2025. Insperity maintained full-year adjusted EBITDA guidance of $170 million to $230 million, citing expectations for continued margin recovery and operating expense savings to offset the lower unit outlook.
Allison said Insperity now expects a full-year adjusted EPS range of $1.60 to $2.60, reflecting a forecast 36% effective tax rate and an estimated 38.5 million weighted average shares outstanding for the remainder of the year.
For Q2 2026, Insperity guided to average paid WSEs of 302,500 to 304,500 (down 1.5% to 2.1% year over year), adjusted EBITDA of $18 million to $46 million, and adjusted EPS of $0.02 to $0.50. Allison again pointed to a flatter quarterly earnings pattern due to the UnitedHealthcare pooling change and the expectation that margin recovery impacts become more pronounced later in the year.
In the Q&A, Allison said management now expects gross profit per employee to be “a little bit higher than what we had in our original guidance,” citing being “a little bit ahead of schedule” on profit recovery efforts. Sarvadi said competitive pricing pressure has increased amid higher benefit costs and more client “shopping,” but argued HRScale provides “a significant competitive differentiation.”
Sarvadi also discussed Insperity’s AI strategy, saying the company is implementing AI internally in HR and payroll and plans to expand an “HR360 agent” to help clients navigate the platform. He said a future version will introduce conversational reporting using demographic and transaction data.
Closing the call, Sarvadi said Insperity was “excited that we have reached that first milestone of our profit recovery,” adding that the company will continue working to regain growth momentum as 2026 progresses.
About Insperity (NYSE:NSP)
Insperity, Inc is a leading provider of human resources and business performance solutions designed to help small and midsize businesses operate more efficiently. Headquartered in Kingwood, Texas, the company offers a comprehensive suite of products and services that span workforce management, payroll administration, employee benefits, risk management, and talent development. By leveraging its proprietary technology platform and team of HR experts, Insperity enables clients to focus on core business objectives while outsourcing complex administrative functions.
The company's flagship offering is its Professional Employer Organization (PEO) service, which allows clients to outsource critical HR tasks such as payroll processing, workers' compensation administration, and compliance with employment regulations.
Four leading AI models discuss this article
"The shift toward margin recovery is masking fundamental weakness in unit growth that the HRScale offering has yet to prove it can reverse."
Insperity is in a classic 'margin over growth' transition, which is a dangerous place to be for a PEO. While beating Q1 EPS expectations is a positive signal for their cost-restructuring efforts, the 1% decline in WSEs and the lowered outlook for 2026 growth suggest the core business is losing momentum. The shift in the UnitedHealthcare contract effectively back-loads earnings risk to the second half of the year, creating significant uncertainty. Until HRScale proves it can offset the 'success penalty' and stem the tide of client attrition, the valuation remains sensitive to macro headwinds. I am cautious about the sustainability of these margins if the competitive landscape forces further pricing concessions.
If the HRScale rollout gains traction as a lower-cost, high-tech alternative, Insperity could capture the mid-market segment more efficiently than its traditional PEO model, leading to a massive valuation re-rating.
"Declining WSEs and lowered FY guide despite the beat underscore demand fragility in SMBs, with maintained EBITDA hinging on benefits cost control and untested HRScale ramp-up."
Insperity's Q1 beat on adjusted EPS ($1.31) and EBITDA ($103M) reflects tangible margin progress—gross profit per WSE at $332/month, benefits costs up only 5% vs 9% trend—but core PEO volumes are shrinking: WSEs down 1% to 303k, new sales -7%, FY guide cut to 303-307k amid 11% attrition and softening SMB survey (54% expect negative macro impact, up from 42%). UHC deal back-loads earnings, Q2 EPS guide $0.02-$0.50 signals lumpiness; HRScale's 6k committed WSEs is promising but unproven at scale vs 300k base. Maintained EBITDA ($170-230M) assumes flawless execution on volatile benefits and expenses.
Margin recovery is ahead of schedule per management, offsetting unit weakness while HRScale addresses the 'success penalty' with committed beta traction and mid-market differentiation, positioning NSP for 2027 growth reacceleration.
"NSP is executing a profitable retreat—margin recovery is real, but the company is shrinking its way to profitability while growth remains elusive and SMB demand is visibly softening."
NSP beat Q1 on margin recovery (gross profit inflection from -21% to -3% YoY) and expense discipline, but the headline masks a deteriorating growth picture: WSE guidance cut to 303k–307k (flat to -2.3%), new client sales down 7%, and attrition at 11% (high end of range). Management is explicitly trading growth for profitability. The UnitedHealthcare pooling change ($1M to $500k limit) back-loads earnings and flattens Q2 guidance to $0.02–$0.50 EPS—a massive range suggesting genuine uncertainty. HRScale (6,000 WSE commitments) is positioned as a growth lever, but it's unproven, and the company's own survey shows SMB sentiment deteriorating sharply (54% now expect negative impact vs. 42% in January). Margin recovery is real; growth recovery is speculative.
If HRScale gains traction faster than expected and the UnitedHealthcare backend loading proves conservative, NSP could re-rate on margin + growth upside. The 41% tax rate is a one-time anomaly tied to stock price, not structural.
"Near-term upside hinges on HRScale uptake and SMB demand stabilizing; without that, margin recovery remains fragile and the stock could reprice lower."
Insperity's Q1 beat sits atop a fragile growth trajectory. The margin-recovery plan looks credible, but 1Q 2026 WSE slipped to 303,049 (-1% YoY) and new-client sales weakened while attrition hovered at the high end of historical ranges. The core uncertainty is macro visibility for SMBs and the pace of HRScale adoption, which management ties to roughly 6,000 WSE commitments over the next six months. The UnitedHealthcare pooling change re-stages seasonality and could push cash and earnings into later quarters, making near-term visibility patchier. Guidance is wide: EBITDA of $170–$230 million and EPS of $1.60–$2.60 imply modest growth unless demand stabilizes and pricing gains endure.
But if HRScale proves durable and pricing gains stick, the margin recovery could accelerate and the stock could re-rate; a stronger H2 could outsize the Q2 scare. A stabilizing SMB cycle would also reduce the earnings volatility caused by seasonality shifts.
"The UHC contract change shifts catastrophic insurance risk onto Insperity's balance sheet, making margin stability highly vulnerable to unpredictable health claims."
Claude and Grok are fixated on the PEO volume decline, but you are all ignoring the structural risk of the UHC contract shift. By moving to a $500k pooling limit, Insperity is effectively self-insuring a larger portion of catastrophic claims volatility. If Q2 or Q3 sees a spike in large-group health events, that 'margin recovery' will evaporate instantly. This isn't just a timing shift; it is a fundamental increase in underwriting risk disguised as an operational efficiency.
"UHC risk is acknowledged in guides, but SMB macro signals deeper pricing pressure nobody flagged."
Gemini, the UHC pooling limit cut to $500k does heighten cat claim exposure, but management maintained full-year EBITDA ($170-230M) post-shift, implying priced-in reserves or reinsurance—real volatility test is Q2's $0.02-$0.50 EPS range amid 11% attrition. Overlooked: SMB survey jump (54% vs 42%) signals pricing power erosion, threatening gross profit/WSE sustainability beyond Q1's $332 inflection.
"Pricing erosion and underwriting volatility are separate risks; simultaneous occurrence breaks the margin recovery thesis."
Grok flags pricing power erosion via SMB survey data—54% expecting negative macro impact is material—but conflates two risks. The pooling shift creates *claim volatility*, while pricing pressure creates *margin compression*. Management maintained EBITDA guidance post-UHC change, yes, but that assumes Q2–Q4 claims normalcy. If both pressures hit simultaneously (macro downturn + elevated cat claims), the $170M floor collapses. The wide Q2 EPS range ($0.02–$0.50) already prices uncertainty; what's missing is correlation risk between demand softness and adverse selection in remaining book.
"UHC-related margin recovery may be eroded by cash-flow volatility from larger-scale claims, so a margin-only rebound may not re-rate NSP without durable HRScale-driven growth."
Gemini, you’re right the UHC shift raises tail underwriting risk, but EBITDA guidance assumes reserves/reeinsurance cushion. The real test is cash-flow volatility if large claims spike; 11% attrition plus 54% SMB negative outlook threaten conversion risk on HRScale. The key is whether HRScale yields durable margin leverage or simply reweights risk into the back half. If Q2 misses or Q3 spikes, a margin-only recovery won’t re-rate NSP.
Panelists agree that Insperity's margin recovery is fragile, with core PEO volumes shrinking and significant uncertainty around the UnitedHealthcare contract shift and macroeconomic conditions. Growth recovery is speculative, and the valuation remains sensitive to macro headwinds.
HRScale's 6k committed WSEs is promising but unproven at scale vs 300k base.
The shift in the UnitedHealthcare contract effectively back-loads earnings risk to the second half of the year, creating significant uncertainty and a fundamental increase in underwriting risk.